High Tower Advisors, LLC Summit Therapeutics Inc. Transaction History
High Tower Advisors, LLC
- $71.6 Billion
- Q4 2024
A detailed history of High Tower Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 39,317 shares of SMMT stock, worth $836,272. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,317
Previous 39,157
0.41%
Holding current value
$836,272
Previous $857,000
18.2%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
82.9MCall Options Held
1.67MPut Options Held
2.64M-
Baker Bros. Advisors LP New York, NY24.4MShares$520 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$248 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$168 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$139 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$119 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.28B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...